PTC Therapeutics (PTCT) Competitors $48.74 +1.09 (+2.29%) Closing price 04:00 PM EasternExtended Trading$48.78 +0.04 (+0.09%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT vs. ITCI, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, and VRNAShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Intra-Cellular Therapies (NASDAQ:ITCI) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings. Is ITCI or PTCT more profitable? PTC Therapeutics has a net margin of 33.56% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% PTC Therapeutics 33.56%-78.56%32.11% Which has preferable earnings and valuation, ITCI or PTCT? Intra-Cellular Therapies has higher earnings, but lower revenue than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64PTC Therapeutics$806.78M4.79-$363.30M$6.517.49 Do institutionals and insiders believe in ITCI or PTCT? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts recommend ITCI or PTCT? Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. PTC Therapeutics has a consensus price target of $65.00, indicating a potential upside of 33.36%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more risk & volatility, ITCI or PTCT? Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Does the media refer more to ITCI or PTCT? In the previous week, PTC Therapeutics had 7 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 8 mentions for PTC Therapeutics and 1 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.00 beat PTC Therapeutics' score of -0.31 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPTC Therapeutics beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.78B$2.90B$5.51B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E Ratio7.4921.0128.0520.16Price / Sales4.79295.02438.35127.91Price / CashN/A41.8337.0657.97Price / Book-3.427.868.125.62Net Income-$363.30M-$54.95M$3.16B$248.50M7 Day Performance-0.83%6.24%4.40%5.54%1 Month Performance-5.71%5.70%4.09%7.52%1 Year Performance54.48%8.08%34.53%22.06% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics4.2874 of 5 stars$48.74+2.3%$65.00+33.4%+50.2%$3.78B$806.78M7.491,410ITCIIntra-Cellular Therapies0.7269 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S4.0603 of 5 stars$20.66+0.8%$37.60+82.0%-16.6%$13.25B$3.12B11.742,682News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.7856 of 5 stars$15.03-0.3%$16.95+12.8%-4.7%$12.55B$3.81B22.7727,811QGENQiagen3.8788 of 5 stars$48.07+0.6%$49.40+2.8%+22.3%$10.69B$1.98B120.525,765MRNAModerna4.4616 of 5 stars$27.59+1.6%$46.61+68.9%-72.1%$10.67B$3.24B-3.165,800ASNDAscendis Pharma A/S3.4929 of 5 stars$172.60+0.2%$220.67+27.8%+23.2%$10.55B$393.54M-27.481,017VTRSViatris3.3379 of 5 stars$8.93-0.9%$10.40+16.5%-12.7%$10.48B$14.74B-2.8232,000BPMCBlueprint Medicines1.5416 of 5 stars$128.18+0.1%$128.06-0.1%+10.4%$8.28B$562.12M-51.89640News CoverageInsider TradeBBIOBridgeBio Pharma4.6844 of 5 stars$43.18-3.7%$58.85+36.3%+65.2%$8.20B$221.90M-12.23400Analyst UpgradeGap UpHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share1.7442 of 5 stars$94.58+0.8%$101.10+6.9%+410.6%$8.05B$42.28M-47.2930Trending NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives RDY Alternatives QGEN Alternatives MRNA Alternatives ASND Alternatives VTRS Alternatives BPMC Alternatives BBIO Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTCT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
